The Limited Times

Now you can see non-English news...

Biontech is investigating Corona variant

2021-11-26T13:17:26.481Z


The Mainz vaccine manufacturer Biontech is looking at the new variant of the coronavirus found in southern Africa in tests and is expecting findings in two weeks at the latest. "We can understand the concerns of experts and immediately initiated investigations into variant B.1.1.529," said the company in Mainz on Friday on request.


The Mainz vaccine manufacturer Biontech is looking at the new variant of the coronavirus found in southern Africa in tests and is expecting findings in two weeks at the latest.

"We can understand the concerns of experts and immediately initiated investigations into variant B.1.1.529," said the company in Mainz on Friday on request.

Mainz - The variant differs significantly from the variants observed so far, as it has additional mutations on the spike protein.

The data from ongoing laboratory tests would provide information on whether an adaptation of the vaccine would be necessary if this variant spreads internationally.

also read

US immunologist Fauci warns of novel coronaviruses

Anthony Fauci doesn't think the pandemic can be eradicated until next summer.

And paints some gloomy pictures in the process.

US immunologist Fauci warns of novel coronaviruses

US experts clear the way for Biontech vaccination for children

In the United States, children under twelve could be vaccinated against Corona as early as November.

As soon as the US drug authority has given its final okay, the government plans to deliver 15 million doses of vaccine.

US experts clear the way for Biontech vaccination for children

Biontech reaps billions in profits

The success of its corona vaccine continues to ensure brilliant business figures for the Mainz-based company.

The capital of Rhineland-Palatinate is also pleased about this: tax revenues are gushing up there.

Biontech reaps billions in profits

Biontech also announced that, together with US partner Pfizer, preparations had been made months ago to adapt the vaccine within six weeks in the event of a so-called escape variant of the virus and to deliver the first batches within 100 days.

To this end, clinical studies with “variant-specific vaccines” have been started in order to collect data on safety and tolerability.

In the event of an adjustment, these could be presented to the authorities as sample data.

An escape variant is a virus variant that defies the effects of the vaccines currently available.

dpa

Source: merkur

All news articles on 2021-11-26

You may like

News/Politics 2024-02-22T13:33:31.249Z

Trends 24h

News/Politics 2024-04-18T09:29:37.790Z
News/Politics 2024-04-18T11:17:37.535Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.